Pharvaris director sells 2,400 shares via 10b5-1

Pharvaris N.V. director Johannes Gerardus Christiaan Petrus Schikan reported an open-market sale of 2,400 shares of common stock.

Rhea-AI Filing Summary

Pharvaris N.V. director Johannes Gerardus Christiaan Petrus Schikan reported an open-market sale of 2,400 shares of common stock. The shares were sold at a weighted average price of $35.1041 per share under a pre-arranged Rule 10b5-1 trading plan, with individual trade prices ranging from $35.00 to $35.30. After this transaction, Schikan directly holds 352,767 shares of Pharvaris common stock.

Insider Trade Summary 10b5-1

Net Seller: 2,400 shares

Net Sell 1 txn

Insider Schikan Johannes Gerardus Christiaan Petrus

Role Director

Sold 2,400 shs ($84K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,400	$35.1041	$84K

Holdings After Transaction: Common Stock — 352,767 shares (Direct)

Footnotes (2)

1. F1. This is a scheduled sale from 10b5-1 trading plan.
2. F2. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $35.00 to $35.30. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold: 2,400 shares Weighted average sale price: $35.1041 per share Sale price range: $35.00–$35.30 per share +1 more

4 metrics

Shares sold 2,400 shares Open-market sale of common stock

Weighted average sale price $35.1041 per share Average price for shares sold on transaction date

Sale price range $35.00–$35.30 per share Range of prices across multiple transactions

Shares held after transaction 352,767 shares Director’s direct holdings post-sale

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, restricted stock units

3 terms

Rule 10b5-1 trading plan regulatory

"This is a scheduled sale from 10b5-1 trading plan."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The reported price represents a weighted average sale price for shares sold in multiple transactions"

restricted stock units financial

"The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Pharvaris (PHVS) report in this Form 4?

Pharvaris reported that director Johannes G.C.P. Schikan sold 2,400 shares of common stock. The transaction was an open-market sale executed under a Rule 10b5-1 trading plan at a weighted average price of $35.1041 per share.

At what price did the Pharvaris (PHVS) director sell shares?

The director’s 2,400 Pharvaris shares were sold at a weighted average price of $35.1041. Individual trades on the transaction date occurred in a price range between $35.00 and $35.30 per share, according to the reported Form 4 footnote.

How many Pharvaris (PHVS) shares does the director hold after the sale?

Following the reported transaction, director Johannes G.C.P. Schikan directly holds 352,767 Pharvaris common shares. This post-transaction holding figure comes from the Form 4 and reflects his position after selling 2,400 shares in the open market.

Was the Pharvaris (PHVS) insider sale made under a Rule 10b5-1 plan?

Yes. The Form 4 states the 2,400-share sale was a scheduled transaction under a Rule 10b5-1 trading plan. Such plans pre-arrange trades, which can indicate the timing was not based on short-term market developments or new, undisclosed information.

Does the Pharvaris (PHVS) Form 4 involve any derivative securities or options?

No derivative securities are reported in this Form 4. The filing lists a single non-derivative transaction: an open-market sale of 2,400 shares of Pharvaris common stock, with no option exercises or other derivative activity disclosed in the derivative summary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 06:18 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schikan Johannes Gerardus Christiaan Petrus

(Last) (First) (Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/29/2026		S(1)		2,400	D	$35.1041(2)	352,767	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This is a scheduled sale from 10b5-1 trading plan.

2. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $35.00 to $35.30. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

	/s/ Marnus Nel, Attorney-in-Fact for Johannes Schikan	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)